Cargando…

Targeting IL‐11 in the treatment of BK virus‐associated haemorrhagic cystitis—A promising new approach

The BK polyomavirus (BKPyV) has pathogenic relevance especially in immunocompromised patients. No causal therapy has been established yet. Therefore, new therapeutic targets need to be identified in experimental studies. A 3D organotypic cell culture model with primary urothelial cells and fibroblas...

Descripción completa

Detalles Bibliográficos
Autores principales: Schneidewind, Laila, Neumann, Thomas, Krüger, William, Hakenberg, Oliver Walther, Schmidt, Christian A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417724/
https://www.ncbi.nlm.nih.gov/pubmed/32588533
http://dx.doi.org/10.1111/jcmm.15546
_version_ 1783569557232812032
author Schneidewind, Laila
Neumann, Thomas
Krüger, William
Hakenberg, Oliver Walther
Schmidt, Christian A.
author_facet Schneidewind, Laila
Neumann, Thomas
Krüger, William
Hakenberg, Oliver Walther
Schmidt, Christian A.
author_sort Schneidewind, Laila
collection PubMed
description The BK polyomavirus (BKPyV) has pathogenic relevance especially in immunocompromised patients. No causal therapy has been established yet. Therefore, new therapeutic targets need to be identified in experimental studies. A 3D organotypic cell culture model with primary urothelial cells and fibroblasts was used as infection model. The detection of virus replication was performed with quantitative polymerase chain reaction (qPCR), and immunohistochemistry (IHC) was also used for analysis. Interleukin levels were measured by enzyme‐linked immunosorbent assay (ELISA). Interestingly, the signal transducer and activator of transcription 3 (STAT3) pathway seems to be activated during infection with BKPyV, for example phosphorylated STAT3 is significantly (P < 0.0001) elevated on day 6 following infection. Therefore, we performed ELISAs for involved interleukins in STAT3 pathway. Interleukin 11 (IL‐11) was significantly (P = 0.026) elevated at day 9. Subsequently, 3D cultures were treated with IL‐11 neutralizing antibody. At day 9 following infection, the median virus replication rate is 4.4 × 10(6) copies/ml. The difference to replication rate without treatment was significantly lower at day 6 (P < 0.0001) and at day 9 (P < 0.0001), respectively. STAT3 pathways seem to be involved during BKPyV infection and need further investigation in experimental studies. A very promising target for treatment might be IL‐11.
format Online
Article
Text
id pubmed-7417724
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-74177242020-08-11 Targeting IL‐11 in the treatment of BK virus‐associated haemorrhagic cystitis—A promising new approach Schneidewind, Laila Neumann, Thomas Krüger, William Hakenberg, Oliver Walther Schmidt, Christian A. J Cell Mol Med Original Articles The BK polyomavirus (BKPyV) has pathogenic relevance especially in immunocompromised patients. No causal therapy has been established yet. Therefore, new therapeutic targets need to be identified in experimental studies. A 3D organotypic cell culture model with primary urothelial cells and fibroblasts was used as infection model. The detection of virus replication was performed with quantitative polymerase chain reaction (qPCR), and immunohistochemistry (IHC) was also used for analysis. Interleukin levels were measured by enzyme‐linked immunosorbent assay (ELISA). Interestingly, the signal transducer and activator of transcription 3 (STAT3) pathway seems to be activated during infection with BKPyV, for example phosphorylated STAT3 is significantly (P < 0.0001) elevated on day 6 following infection. Therefore, we performed ELISAs for involved interleukins in STAT3 pathway. Interleukin 11 (IL‐11) was significantly (P = 0.026) elevated at day 9. Subsequently, 3D cultures were treated with IL‐11 neutralizing antibody. At day 9 following infection, the median virus replication rate is 4.4 × 10(6) copies/ml. The difference to replication rate without treatment was significantly lower at day 6 (P < 0.0001) and at day 9 (P < 0.0001), respectively. STAT3 pathways seem to be involved during BKPyV infection and need further investigation in experimental studies. A very promising target for treatment might be IL‐11. John Wiley and Sons Inc. 2020-06-25 2020-08 /pmc/articles/PMC7417724/ /pubmed/32588533 http://dx.doi.org/10.1111/jcmm.15546 Text en © 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Schneidewind, Laila
Neumann, Thomas
Krüger, William
Hakenberg, Oliver Walther
Schmidt, Christian A.
Targeting IL‐11 in the treatment of BK virus‐associated haemorrhagic cystitis—A promising new approach
title Targeting IL‐11 in the treatment of BK virus‐associated haemorrhagic cystitis—A promising new approach
title_full Targeting IL‐11 in the treatment of BK virus‐associated haemorrhagic cystitis—A promising new approach
title_fullStr Targeting IL‐11 in the treatment of BK virus‐associated haemorrhagic cystitis—A promising new approach
title_full_unstemmed Targeting IL‐11 in the treatment of BK virus‐associated haemorrhagic cystitis—A promising new approach
title_short Targeting IL‐11 in the treatment of BK virus‐associated haemorrhagic cystitis—A promising new approach
title_sort targeting il‐11 in the treatment of bk virus‐associated haemorrhagic cystitis—a promising new approach
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417724/
https://www.ncbi.nlm.nih.gov/pubmed/32588533
http://dx.doi.org/10.1111/jcmm.15546
work_keys_str_mv AT schneidewindlaila targetingil11inthetreatmentofbkvirusassociatedhaemorrhagiccystitisapromisingnewapproach
AT neumannthomas targetingil11inthetreatmentofbkvirusassociatedhaemorrhagiccystitisapromisingnewapproach
AT krugerwilliam targetingil11inthetreatmentofbkvirusassociatedhaemorrhagiccystitisapromisingnewapproach
AT hakenbergoliverwalther targetingil11inthetreatmentofbkvirusassociatedhaemorrhagiccystitisapromisingnewapproach
AT schmidtchristiana targetingil11inthetreatmentofbkvirusassociatedhaemorrhagiccystitisapromisingnewapproach